Related Experiment Videos
[Current trends in antihypertensive therapy: pro and con]
1Subkatedra kardiologie I. LF Praha Krc.
Insights
Antihypertensive treatments significantly lower risks of stroke and heart failure. Newer medications offer improved cardiovascular benefits without adverse metabolic effects, guiding personalized hypertension management.
Area of Science:
- Cardiology
- Pharmacology
- Internal Medicine
Context:
- Hypertension management is crucial for preventing severe health complications.
- Established treatments like diuretics and beta-blockers reduce cardiovascular mortality but have metabolic drawbacks.
Purpose:
- To evaluate the efficacy of antihypertensive treatments.
- To compare the impact of different drug classes on cardiovascular events and metabolic risk factors.
Summary:
- Antihypertensive therapy markedly reduces cerebrovascular attacks, cardiac failure, and malignant hypertension.
- While effective for cardiovascular mortality, diuretics and non-selective beta-blockers negatively affect metabolic factors.
- Emerging drug classes like calcium antagonists, ACE inhibitors, and selective alpha-blockers show promise for improving ischemic heart disease outcomes without metabolic compromise.
Impact:
- Highlights the significant benefits of hypertension control on major adverse cardiovascular events.
- Identifies limitations of traditional antihypertensive drugs regarding metabolic side effects.
- Supports a shift towards individualized treatment strategies incorporating newer agents for better risk management, especially in patients with diabetes or hyperlipidemia.
Abstract:
Treatment of hypertension reduced markedly (by more than 40%) the prevalence of cerebrovascular attacks, the prevalence of cardiac failure, malignant hypertension and ophthalmological complications of hypertension. The impact of antihypertensive treatment on the incidence of ischaemic heart disease is less marked. The wide use of diuretics and beta-blockers is supported by the fact that large studies of antihypertensive treatment revealed that they reduced the cardiovascular mortality and morbidity in a marked way. On the other hand, diuretics exert a negative effect on insulin resistance, glucose tolerance, cholesterol and may lead to hypokalaemia and hyperuricaemia. Non-selective beta-blockers are not optimal from the aspect of the risk profile of hypertensive patients. Therefore there is justified hope that wider use of calcium antagonists, beta-blockers of the third generation, ACE inhibitors and selective alpha 1 blockers will have a greater impact on IHD, as these drugs do not exert a negative effect on metabolic risk factors. At present an individual approach to treatment which takes into account other diseases present or complications of hypertension, in particular diabetes and hyperlipoproteinaemia, is the basic approach so far and the basis of therapeutic tactics.